一种用于克服非小细胞肺癌治疗中抗原异质性的多靶向 CAR-T 细胞平台
A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer.
这些发现支持采用多靶点CAR-T 策略来应对NSCLC及可能其他实体瘤中的抗原异质性。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Intratumoral immune triads are required for adoptive T cell therapy-mediated elimination of solid tumors.
Intratumoral immune triads are required for adoptive T cell therapy-mediated elimination of solid tumors.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
在癌症患者中发现的肿瘤反应性CD8 T细胞通常功能失调,无法阻止肿瘤生长。过继性T细胞转移(ACT),即给予大量体外生成的具有细胞溶解能力的肿瘤反应性CD8 T细胞,是一种正在研究中的重要癌症免疫疗法。
然而,ACT的一个局限是转移的CD8 T细胞往往迅速丧失效应功能,并且尽管在某些恶性肿瘤中取得了令人振奋的结果,但很少有ACT临床试验在实体瘤中显示出应答。在这里,我们开发了临床前癌症小鼠模型,以研究在ACT背景下是否以及如何调动肿瘤特异性CD4 T细胞来克服CD8 T细胞功能障碍。对颜色编码的癌细胞、肿瘤特异性CD8和CD4 T细胞以及抗原呈递细胞(APC)进行原位共聚焦显微镜检查,并结合功能研究,揭示CD8和CD4 T细胞的空间定位和相互作用,而非其数量,决定了ACT疗效和抗肿瘤应答。除了已知CD4 T细胞在初始CD8 T细胞启动/激活过程中的必要性外,我们还发现了抗原特异性CD4 T细胞的新作用。
在效应阶段,CD4 T细胞必须与CD8 T细胞以及交叉呈递CD8和CD4肿瘤抗原的APC共同结合,形成三细胞簇(三联体),以许可CD8 T细胞细胞毒性并介导癌细胞清除。三联体形成在转录和表观遗传层面重编程CD8 T细胞,防止T细胞功能障碍/耗竭,并最终导致大型已建立肿瘤的清除,并赋予针对复发的长期保护。当瘤内三联体的形成被破坏时,过继转移的CD8 T细胞无法被重编程,尽管肿瘤浸润CD8和CD4 T细胞数量相等,肿瘤仍会进展。引人注目的是,在接受免疫检查点阻断治疗的肺癌患者肿瘤中,CD4 T细胞::CD8 T细胞::APC三联体的形成与临床反应相关,而CD4::APC二联体或CD8或CD4 T细胞的总体数量则无关,这证明了三联体在人类非ACT setting中的重要性。
我们的工作揭示了瘤内三联体是抗肿瘤免疫的关键要求,以及CD4 T细胞在CD8 T细胞细胞毒性和癌细胞根除中的新作用。
Tumor-reactive CD8 T cells found in cancer patients are frequently dysfunctional, unable to halt tumor growth. Adoptive T cell transfer (ACT), the administration of large numbers of in vitro -generated cytolytic tumor-reactive CD8 T cells, is an important cancer immune therapy being pursued.
However, a limitation of ACT is that transferred CD8 T cells often rapidly lose effector function, and despite exciting results in certain malignancies, few ACT clinical trials have shown responses in solid tumors.
Here, we developed preclinical cancer mouse models to investigate if and how tumor-specific CD4 T cells can be enlisted to overcome CD8 T cell dysfunction in the setting of ACT. In situ confocal microscopy of color-coded cancer cells, tumor-specific CD8 and CD4 T cells, and antigen presenting cells (APC), combined with functional studies, revealed that the spatial positioning and interactions of CD8 and CD4 T cells, but not their numbers, dictates ACT efficacy and anti-tumor responses.
We uncover a new role of antigen-specific CD4 T cells in addition to the known requirement for CD4 T cells during priming/activation of naïve CD8 T cells. CD4 T cells must co-engage with CD8 T cells and APC cross-presenting CD8- and CD4-tumor antigens during the effector phase, forming a three-cell-cluster (triad), to license CD8 T cell cytotoxicity and mediate cancer cell elimination. Triad formation transcriptionally and epigenetically reprogram CD8 T cells, prevent T cell dysfunction/exhaustion, and ultimately lead to the elimination of large established tumors and confer long-term protection from recurrence.
When intratumoral triad formation was disrupted, adoptively transferred CD8 T cells could not be reprogrammed, and tumors progressed despite equal numbers of tumor-infiltrating CD8 and CD4 T cells. Strikingly, the formation of CD4 T cell::CD8 T cell::APC triads in tumors of patients with lung cancers treated with immune checkpoint blockade was associated with clinical responses, but not CD4::APC dyads or overall numbers of CD8 or CD4 T cells, demonstrating the importance of triads in non-ACT settings in humans.
Our work uncovers intratumoral triads as a key requirement for anti-tumor immunity and a new role for CD4 T cells in CD8 T cell cytotoxicity and cancer cell eradication.
MEMBER ACCOUNT
登录成功会直接打开下一页。